DISEASES WE ARE TACKLING AND THE UNMET NEED
While biologic therapies have delivered meaningful efficacy, their injectable
administration, safety considerations, and treatment burden often limit long-term adherence
and delay initiation. These challenges are especially pronounced in patients with mild to
moderate disease, who may be reluctant to start injectable therapies or are not considered
appropriate candidates under current treatment paradigms. As a result, a substantial patient
population remains underserved, leading to ongoing disease activity and diminished quality
of life.
ADDRESSING THE UNMET NEED
Our proprietary de novo discovery platform enables the design of oral peptides
optimized for stability, permeability, and target engagement. This allows us to pursue
clinically validated targets while reimagining them as oral therapies suitable for broader
patient populations. By moving beyond injection-only paradigms, we aim to expand access to
targeted therapies and improve long-term disease control.
Partnerships
We value collaboration and actively seek strategic partnerships that can help accelerate the development and delivery of our medicines to patients. If you are interested in exploring potential opportunities to work together, we welcome you to connect with us. Please reach out to our Business Development team at
[email protected] for all partnership and collaboration inquiries.